63815-39-4

Basic information

• Product Name: 3-(4-methoxyphenoxy)propanenitrile
• Synonyms: 3-(4-methoxyphenoxy)propanenitrile
• CAS NO: 63815-39-4
• Molecular Formula: C₁₀H₁₁NO₂
• Molecular Weight: 177.2
• Mol File: 63815-39-4.mol
• Article Data: 22

Chemical Properties

• Melting Point: 63-64.5 °C(Solv: ethanol (64-17-5))
• Boiling Point: 335.2°C at 760 mmHg
• Flash Point: 136.7°C
• Appearance: /
• Density: 1.081g/cm³
• Vapor Pressure: 0.000121mmHg at 25°C
• Refractive Index: 1.507
• CAS DataBase Reference: 3-(4-methoxyphenoxy)propanenitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-methoxyphenoxy)propanenitrile(63815-39-4)
• EPA Substance Registry System: 3-(4-methoxyphenoxy)propanenitrile(63815-39-4)

Safety Data

• Hazardous Substances Data: 63815-39-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H11NO2/c1-12-9-3-5-10(6-4-9)13-8-2-7-11/h3-6H,2,8H2,1H3

Upstream product

• 150-76-5 4-methoxy-phenol 
• 107-13-1 acrylonitrile 
• 100-85-6 N-benzyl-trimethylammonium hydroxide 
• 109-78-4 3-Hydroxypropionitrile 

Downstream Products

• 3034-04-6 6-methoxyflavanone 
• 1370544-73-2 1-((4-(4-fluorophenyl)-6-methoxy-2H-chromen-3-yl)methyl)pyrrolidine 
• 909272-20-4 n-butyl (R)-2-[3-[N-[3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyrate 
• 907192-61-4 n-butyl (R)-2-[3-[[benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoate 
• 1092467-10-1 N-[2-hydroxy-2-(2,3-dihydrobenzo[β][1,4]dioxin-6-yl)-1-pyrrolidin-1-ylmethyl-ethyl]-3-(4-methoxy-phenoxy)-propionamide L-tartrate 

Relevant articles and documents

Design, synthesis and preliminary bioactivity evaluation of bitopic benzopyranomorpholine analogues as selective dopamine D3 receptor ligands as anti-drug addiction therapeutic agents

Three series of bitopic benzopyranomorpholine analogues were designed, synthesized, and evaluated as a novel class of selective ligands for the dopamine D3 receptor. Binding affinities of target compounds were determined using the method of radioligand binding assay. Most compounds demonstrated considerable binding affinities and selectivity for D3 receptor. Besides, the compounds were screened for their ability to alleviate withdrawal symptoms of opioid addiction in animal behavioral models. The results showed that compound 20h displayed nanomolar affinity for the D3R, and exhibited anti-drug addiction efficacy in the animal model of of naloxone-induced withdrawal symptoms in morphine-dependent mice.

CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION

The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.

METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES

PROBLEM TO BE SOLVED: To provide a method of treating polycystic kidney diseases with ceramide derivatives. SOLUTION: A pharmaceutical composition for treating polycystic kidney disease in a subject comprises an effective amount of a predetermined compoun